MediWound (NASDAQ:MDWD) Stock Passes Below 50 Day Moving Average - What's Next?

Key Points

• MediWound's stock (NASDAQ:MDWD) fell below its 50-day moving average, trading at $17.86 after reaching a low of $17.77.
• Recent analyst reports show a shift in sentiment, with Wall Street Zen downgrading the stock from "hold" to "sell," while Oppenheimer set a target price of $34.00.
• MediWound reported a quarterly earnings loss of ($1.23) EPS, significantly missing analysts' estimates, with a negative net margin of 142.18%.

MediWound Ltd. (NASDAQ:MDWD - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $18.18 and traded as low as $17.77. MediWound shares last traded at $17.86, with a volume of 70,107 shares traded.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MDWD. Wall Street Zen lowered MediWound from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. Oppenheimer began coverage on MediWound in a research report on Monday, June 2nd. They set an "outperform" rating and a $34.00 target price for the company. Finally, Zacks Research lowered MediWound from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, MediWound has a consensus rating of "Moderate Buy" and a consensus target price of $32.25.

MediWound Stock Performance

The firm has a market cap of $193.03 million, a price-to-earnings ratio of -6.77 and a beta of 0.25. The business has a 50 day simple moving average of $18.18 and a 200-day simple moving average of $18.47.

MediWound (NASDAQ:MDWD - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.68). The company had revenue of $5.71 million for the quarter, compared to analyst estimates of $5.68 million. MediWound had a negative net margin of 142.18% and a negative return on equity of 96.71%. As a group, research analysts anticipate that MediWound Ltd. will post -2.66 earnings per share for the current year.

Hedge Funds Weigh In On MediWound

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Yelin Lapidot Holdings Management Ltd. boosted its stake in shares of MediWound by 0.8% in the 1st quarter. Yelin Lapidot Holdings Management Ltd. now owns 858,000 shares of the biopharmaceutical company's stock worth $13,316,000 after buying an additional 6,639 shares during the last quarter. Silverberg Bernstein Capital Management LLC boosted its stake in shares of MediWound by 41.9% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 147,535 shares of the biopharmaceutical company's stock worth $2,858,000 after buying an additional 43,591 shares during the last quarter. ARK Investment Management LLC boosted its stake in shares of MediWound by 6.7% in the 1st quarter. ARK Investment Management LLC now owns 106,930 shares of the biopharmaceutical company's stock worth $1,660,000 after buying an additional 6,684 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of MediWound by 104.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,062 shares of the biopharmaceutical company's stock worth $505,000 after buying an additional 13,312 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of MediWound by 17.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 22,468 shares of the biopharmaceutical company's stock worth $349,000 after buying an additional 3,343 shares during the last quarter. Hedge funds and other institutional investors own 46.83% of the company's stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.